157 related articles for article (PubMed ID: 34744754)
1. Corrigendum: Targeting Myc Interacting Proteins as a Winding Path in Cancer Therapy.
Zhou Y; Gao X; Yuan M; Yang B; He Q; Cao J
Front Pharmacol; 2021; 12():785732. PubMed ID: 34744754
[TBL] [Abstract][Full Text] [Related]
2. Targeting Myc Interacting Proteins as a Winding Path in Cancer Therapy.
Zhou Y; Gao X; Yuan M; Yang B; He Q; Cao J
Front Pharmacol; 2021; 12():748852. PubMed ID: 34658888
[No Abstract] [Full Text] [Related]
3. Corrigendum: Evaluation of Riboflavin Transporters as Targets for Drug Delivery and Theranostics.
Bartmann L; Schumacher D; von Stillfried S; Sternkopf M; Alampour-Rajabi S; van Zandvoort MAMJ; Kiessling F; Wu Z
Front Pharmacol; 2020; 11():617329. PubMed ID: 33324229
[TBL] [Abstract][Full Text] [Related]
4. Corrigendum: Paraptosis: a unique cell death mode for targeting cancer.
Hanson S; Dharan A; V JP; Pal S; Nair BG; Kar R; Mishra N
Front Pharmacol; 2023; 14():1274076. PubMed ID: 37745056
[TBL] [Abstract][Full Text] [Related]
5. Corrigendum: Molecular Docking as a Therapeutic Approach for Targeting Cancer Stem Cell Metabolic Processes.
Arjmand B; Kokabi Hamidpour S; Alavi-Moghadam S; Yavari H; Shahbazbadr A; Rezaei-Tavirani M; Gilany K; Larijani B
Front Pharmacol; 2022; 13():892656. PubMed ID: 35586055
[TBL] [Abstract][Full Text] [Related]
6. Corrigendum: COE Inhibits Vasculogenic Mimicry by Targeting EphA2 in Hepatocellular Carcinoma, a Research Based on Proteomics Analysis.
Chu Z; Shi X; Chen G; He X; Qian Y; Wang H; Tao L; Liu Y; Jiang W; Chen J
Front Pharmacol; 2021; 12():831941. PubMed ID: 35069227
[TBL] [Abstract][Full Text] [Related]
7. Corrigendum: Anakinra Therapy for Non-cancer Inflammatory Diseases.
Cavalli G; Dinarello CA
Front Pharmacol; 2019; 10():148. PubMed ID: 30906259
[TBL] [Abstract][Full Text] [Related]
8. Corrigendum: Dosage Modification of Traditional Chinese Medicine Prescriptions: An Analysis of Two Randomized Controlled Trials.
Zhou R; Zheng Y; An X; Jin D; Lian F; Tong X
Front Pharmacol; 2022; 13():844063. PubMed ID: 35370656
[TBL] [Abstract][Full Text] [Related]
9. Corrigendum: A Matrine Derivative M54 Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss by Targeting Ribosomal Protein S5.
Xin Z; Jin C; Chao L; Zheng Z; Liehu C; Panpan P; Weizong W; Xiao Z; Qingjie Z; Honggang H; Longjuan Q; Xiao C; Jiacan S
Front Pharmacol; 2021; 12():. PubMed ID: 33981210
[TBL] [Abstract][Full Text] [Related]
10. Corrigendum: Confused Connections? Targeting White Matter to Address Treatment Resistant Schizophrenia.
Crocker CE; Tibbo PG
Front Pharmacol; 2018; 9():1417. PubMed ID: 30555331
[TBL] [Abstract][Full Text] [Related]
11. Corrigendum: Targeting Anion Exchange of Osteoclast, a New Strategy for Preventing Wear Particles Induced-Osteolysis.
Wu C; Liu X; Sun R; Qin Y; Liu Z; Yang S; Tang T; Zhu Z; Yu D; Liu F
Front Pharmacol; 2019; 10():1078. PubMed ID: 31588207
[TBL] [Abstract][Full Text] [Related]
12. Corrigendum: Advances in the roles of glycyrrhizic acid in cancer therapy.
Zhang Y; Sheng Z; Xiao J; Li Y; Huang J; Jia J; Zeng X; Li L
Front Pharmacol; 2023; 14():1345663. PubMed ID: 38155900
[TBL] [Abstract][Full Text] [Related]
13. Corrigendum: Prostaglandin reductase 1 as a potential therapeutic target for cancer therapy.
Wang X; Yin G; Zhang W; Song K; Zhang L; Guo Z
Front Pharmacol; 2023; 14():1220144. PubMed ID: 37305537
[TBL] [Abstract][Full Text] [Related]
14. Corrigendum: Docetaxel-loaded novel nano-platform for synergistic therapy of non-small cell lung cancer.
Feng X; Xiong X; Ma S
Front Pharmacol; 2022; 13():964540. PubMed ID: 36160393
[TBL] [Abstract][Full Text] [Related]
15. Corrigendum: Formulation and development of transferrin targeted solid lipid nanoparticles for breast cancer therapy.
Bhagwat GS; Athawale RB; Gude RP; Md S; Alhakamy NA; Fahmy UA; Kesharwani P
Front Pharmacol; 2022; 13():1123542. PubMed ID: 36712681
[TBL] [Abstract][Full Text] [Related]
16. Corrigendum: Danshensu methyl ester enhances autophagy to attenuate pulmonary fibrosis by targeting lncIAPF-HuR complex.
Zhu Q; Wang J; Ji Y; Luan J; Yue D; Liu W; Li H; Zhang J; Qu G; Lv C; Song X
Front Pharmacol; 2022; 13():1086927. PubMed ID: 36534046
[TBL] [Abstract][Full Text] [Related]
17. Corrigendum: Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents.
Ladin DA; Soliman E; Griffin L; Van Dross R
Front Pharmacol; 2021; 12():732903. PubMed ID: 34335283
[TBL] [Abstract][Full Text] [Related]
18. Corrigendum: Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice.
Choudhari AS; Mandave PC; Deshpande M; Ranjekar P; Prakash O
Front Pharmacol; 2020; 11():175. PubMed ID: 32184731
[TBL] [Abstract][Full Text] [Related]
19. Corrigendum: Shikonin Inhibits Cancer Through P21 Upregulation and Apoptosis Induction.
Wang F; Mayca Pozo F; Tian D; Geng X; Yao X; Zhang Y; Tang J
Front Pharmacol; 2020; 11():1088. PubMed ID: 32765281
[TBL] [Abstract][Full Text] [Related]
20. Corrigendum: Adenosine kinase on deoxyribonucleic acid methylation: Adenosine receptor-independent pathway in cancer therapy.
Luo HY; Shen HY; Perkins RS; Wang YX
Front Pharmacol; 2023; 14():1200491. PubMed ID: 37124214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
